Clinical Trial Update: Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on Givastomig combined with nivolumab and chemotherapy for CLDN18.2-positive metastatic gastric cancer; the study is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Carcinoma

Drugs mentioned

• Givastomig (TJ033721)
• nivolumab (nivolumab)

Snippet

Sponsor: I-Mab Biopharma US Limited | Conditions: Solid Tumor, Advanced Cancer | Phase 2 | Status: RECRUITING